GLP-3 (Retatrutide) Triple Agonist Research: Published Studies Reviewed
A factual review of peer-reviewed studies on retatrutide, a triple GIP, GLP-1, and glucagon receptor agonist being investigated for its effects on metabolic function, energy expenditure, and body composition.
GLP-3 (Retatrutide): Overview
Retatrutide is a synthetic peptide that acts simultaneously at three receptors: glucose-dependent insulinotropic polypeptide receptor (GIPR), glucagon-like peptide-1 receptor (GLP-1R), and glucagon receptor (GCGR). This triple-agonist profile adds glucagon receptor activity to the GIP/GLP-1 dual agonism seen in tirzepatide, with glucagon's role in energy expenditure and lipolysis representing the primary mechanistic differentiation.
The following review presents key findings from published research without therapeutic claims or dosage recommendations. All findings are from clinical or preclinical research contexts.
Study 1: Phase 2 Trial — Body Composition and Metabolic Markers
Jastreboff et al. (2023, NEJM) published Phase 2 trial data on retatrutide in adults with obesity. The 24-week, dose-ranging study evaluated multiple doses including 1mg, 4mg, 8mg, and 12mg once-weekly.
Key observations from the Phase 2 trial included:
- Dose-dependent weight reductions across all active groups vs. placebo
- Significant reductions in waist circumference and visceral adipose tissue markers
- Improvements in triglycerides, LDL cholesterol, and systolic blood pressure
- Most common adverse effects were gastrointestinal (nausea, vomiting, diarrhea) — typical of incretin-class agents
- No dose-limiting toxicity signals at doses up to 12mg in the study period
The Role of Glucagon Receptor Agonism
The addition of glucagon receptor (GCGR) activity is the key mechanistic distinction of triple agonists vs. dual incretin agonists. Glucagon has historically been studied for its role in hepatic glucose output, but also plays roles in fatty acid oxidation, thermogenesis, and energy expenditure.
| Receptor | Primary Research-Documented Roles |
|---|---|
| GIP receptor (GIPR) | Incretin effect, adipocyte lipid modulation, potential GLP-1 nausea attenuation |
| GLP-1 receptor (GLP-1R) | Reduced gastric emptying, appetite suppression, insulin secretion |
| Glucagon receptor (GCGR) | Hepatic fat oxidation, thermogenesis, energy expenditure — distinguishing mechanism |
The challenge in triple-agonist design is balancing GCGR-driven energy expenditure against GCGR's hyperglycemic potential. Retatrutide's structure appears tuned to favor net glucose-lowering through the dominant incretin effects while leveraging GCGR's thermogenic and lipolytic properties.
Molecular Profile
| Property | Value |
|---|---|
| Molecular weight | ~4,945 Da |
| Receptor targets | GIPR, GLP-1R, GCGR (triple agonist) |
| Plasma half-life | ~6 days (C20 fatty diacid albumin-binding) |
| Dosing in Phase 2 | Once-weekly subcutaneous administration |
| Storage | Lyophilized: -20°C; Reconstituted: 2–8°C, use within 30 days |
Quick Reference Summary
- Mechanism: Triple GIP, GLP-1, and glucagon receptor agonist
- Key differentiator: Glucagon receptor activity adds thermogenic and lipolytic effects vs. dual agonists
- Phase 2 finding: 17.5% mean body weight reduction at 24 weeks (12mg arm)
- Tolerability: GI adverse effects consistent with incretin class
- Research status: Phase 2 human data published (2023); Phase 3 ongoing
- Use context: Research-grade compound for in vitro and preclinical laboratory use only